PolyPid Ltd. announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. There are currently approximately 40 centers open. The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is expected to occur in mid-2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.752 USD | -1.12% | +8.01% | +25.07% |
Feb. 14 | Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024 | |
Feb. 14 | PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.07% | 22.8M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PYPD Stock
- News PolyPid Ltd.
- PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial